FOLFOX方案与贝伐珠单抗共同治疗晚期结肠癌的临床研究

Clinical Study of FOLFOX Regimen Combined with Bevacizumab in Treatment of Advanced Colon Cancer

目的:探讨FOLFOX方案与贝伐珠单抗共同治疗晚期结肠癌的价值。方法:选取2017年1月-2018年7月本院收治的52例晚期结肠癌患者为研究对象,按照随机数字表法将其分为对照组和观察组,各26例。对照组给予FOLFOX方案,观察组给予FOLFOX方案联合贝伐珠单抗治疗。比较两组治疗效果、不良反应、功能状态评分(KPS)、血清肿瘤标志物浓度(CEA、CA242)。结果:经治疗后,观察组病情总缓解率为73.08%,高于对照组的38.46%(P<0.05);对照组KPS评分低于观察组(P<0.05);观察组CEA、CA242浓度均低于对照组(P<0.05);观察组不良反应发生率为30.77%,低于对照组的65.38%(P<0.05)。结论:对晚期结肠癌患者给予FOLFOX方案与贝伐珠单抗联合治疗,提高了临床治疗效果,延长了患者的寿命。

Objective:To explore the value of FOLFOX regimen combined with Bevacizumab in treatment of advanced colon cancer.Method:A total of 52 patients with advanced colon cancer admitted to our hospital from January 2017 to July 2018 were selected.According to the random number table method,they were divided into control group and observation group,26 cases in each group.The control group was given FOLFOX regimen,while observation group was given FOLFOX regimen combined with Bevacizumab.The therapeutic effects,adverse reactions,KPS and serum tumor markers(CEA,CA242)between two groups were compared.Result:After treatment,the total remission rate of observation group was 73.08%,which was higher than 38.46% of control group(P<0.05).The KPS score of control group was lower than that of observation group(P<0.05).The concentration of CEA and CA242 in observation group were lower than those of control group(P<0.05).The incidence of adverse reactions in observation group was 30.77%,which was lower than 65.38% of control group(P<0.05).Conclusion:The combination of FOLFOX regimen and Bevacizumab in patients with advanced colon cancer improves clinical outcomes and prolongs patient life.